KNSA
USDKiniksa Pharmaceuticals International plc Class A Ordinary Shares
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$39.080
Máximo
$39.220
Mínimo
$38.570
Volume
0.35M
Fundamentos da empresa
Capitalização de mercado
2.9B
Setor
Drug Manufacturers - Specialty & Generic
País
United Kingdom
Estatísticas de negociação
Volume médio
0.46M
Bolsa de valores
NMS
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $55
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals with a Buy and raises the price target from $45 to $55.
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $44
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals with a Outperform and raises the price target from $38 to $44.
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.